E. Gabriela Chiorean, MD, highlights the importance of consistently testing for biomarkers with RNA-based tests in addition to DNA-based. She also details key biomarkers and the upcoming 9th Annual School of Gastrointestinal Oncology® conference.
PanCAN’s Scientific & Medical Advisory Board (SMAB) welcomes new leadership and members, representing the foremost expertise in the field of pancreatic cancer from institutions across the US.
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.
No Survival Benefit for Nab-Paclitaxel in Biliary Tract Cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.